David McClure, MD
Internal Medicine · Bel Air, MDNPI 1275538878
Payments from drug & device makers
Across 167 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$928
- Novo Nordisk$333
- AbbVie$220
- Lilly USA, LLC$210
- Johnson & Johnson$200
- GSK$191
- plus $1K from 34 others
What the payments were for
- Food & beverage$3,444100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $928 |
| Novo Nordisk | 17 | $333 |
| AbbVie(2 entities) | 12 | $220 |
| Lilly USA, LLC | 10 | $210 |
| Johnson & Johnson | 12 | $200 |
| GSK | 12 | $191 |
| Dexcom, Inc. | 5 | $105 |
| Sumitomo Pharma America, Inc. | 5 | $96 |
| Abbott | 5 | $94 |
| Pfizer | 5 | $86 |
| Exact Sciences | 3 | $81 |
| Boehringer Ingelheim | 4 | $73 |
| Amarin Pharma, Inc. | 4 | $69 |
| Eisai Inc. | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Amgen | 3 | $48 |
| Genentech USA, Inc. | 2 | $42 |
| Astellas Pharma US Inc | 2 | $40 |
| Bayer | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 1 | $32 |
| Madrigal Pharmaceuticals | 1 | $30 |
| Acadia Pharmaceuticals Inc | 2 | $30 |
| Merck | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Medtronic | 2 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $28 |
| Urovant Sciences Inc | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Dynavax Technologies Corporation | 1 | $24 |
| Neurelis, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Cerapedics Inc. | 1 | $17 |
| Evoke Pharma, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,444 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $39,511 |
| EliquisApixaban | 26 | $28,387 |
| JardianceEmpagliflozin | 16 | $22,869 |
| XareltoRivaroxaban | 14 | $22,416 |
| JanuviaSitagliptin Phosphate | 13 | $20,967 |
| Levothyroxine Sodium | 514 | $8,763 |
| Losartan Potassium | 423 | $6,249 |
| Rosuvastatin Calcium | 324 | $5,882 |
| Atorvastatin Calcium | 441 | $5,419 |
| Varenicline Tartrate | 18 | $5,008 |
| SynthroidLevothyroxine Sodium | 71 | $3,943 |
| Escitalopram Oxalate | 205 | $3,877 |
| Lisinopril | 591 | $3,828 |
| Amlodipine Besylate | 458 | $3,656 |
| Pantoprazole Sodium | 164 | $3,644 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $191 | $39,51140 claims |
| PfizerEliquis | $86 | $28,38726 claims |
| Boehringer IngelheimJardiance | $73 | $22,86916 claims |
| Johnson & JohnsonXarelto | $200 | $22,41614 claims |
| MerckJanuvia | $29 | $20,96713 claims |
| AbbVieSynthroid | $220 | $3,94371 claims |
| AstraZenecaFarxiga | $928 | $2,74112 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $14 | $1,33921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Bel Air
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
- Mark YarchoanBaltimore$2.4M
- Marianne MannHighland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.